A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Hepatitis C

Trial Profile

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2008

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2008 The expected completion date for this trial is now 1 Apr 2006.
    • 20 Dec 2007 Status changed from in progress to completed.
    • 18 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top